A total of 80 patients were involved in the study — 40 people were screened before the first COVID-19 lockdown, and 40 people were screened after.
Researchers found the median circulating tumor DNA concentration among patients diagnosed after the lockdown was higher than those diagnosed before lockdown.
The study suggests that CRC is a major area for intervention to minimize pandemic-associated delays in screening, diagnosis and treatment.
